Company Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.79 ^USD	+3.12%		-16.75%	-0.28%

Mar. 15	North American Morning Briefing : Inflation -2-	DJ
Mar. 14	Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Number of employees: 8

USD in Million	2022	Weight	2023	Weight	Delta
Cytokine-based Therapy 100.0 %	0	nan %	0	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Sanjeev Luther CEO	Chief Executive Officer	62	Dec. 31
Sandra Gurrola DFI	Director of Finance/CFO	57	21-06-20
Megan Yung LAW	General Counsel	-	23-05-23

Members of the board	Title	Age	Since
James Bristol CHM	Chairman	77	23-10-29
William Wexler BRD	Director/Board Member	65	22-06-06
Dorothy Clarke BRD	Director/Board Member	59	23-08-27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,410,331	3,283,683 ( 60.69 %)	0	60.69 %
Stock B	0	156,000	0	0

Name	Equities	%	Valuation
Charles Cherington 10.29 %	556,465	10.29 %	1 M $
Lake Street Advisors Group LLC 9.630 %	520,996	9.630 %	1 M $
George P. Denny 8.451 %	457,238	8.451 %	1 M $
John Halpern 8.360 %	452,283	8.360 %	1 M $
Nicholas Singer 7.172 %	388,036	7.172 %	931 286 $
Freebird Investments LLC 5.038 %	272,583	5.038 %	654 199 $
Factor Bioscience, Inc. 2.385 %	129,033	2.385 %	309 679 $
Purchase Capital LLC 2.252 %	121,822	2.252 %	292 373 $
Cypress Point Wealth Management LLC 1.744 %	94,375	1.744 %	226 500 $
Naviter Wealth LLC 1.456 %	78,796	1.456 %	189 110 $

Eterna Therapeutics, Inc.

1035 Cambridge Street Suite 18A

02141, Cambridge

http://eternatx.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ETERNA THERAPEUTICS INC.	-0.28%	9.68M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research